FDA Approves Nexavar for Thyroid Cancer

Bayer/Onyx drug gains expanded indication

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The FDA has expanded the approved use of the cancer drug Nexavar to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer. Nexavar is made by Bayer AG and Onyx Pharmaceuticals and is also approved to treat advanced kidney cancer and liver cancer. Onyx was acquired by Amgen earlier this year....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters